News Snapshot:
A recombinant COVID-19 fusion protein vaccine (V-01) developed and manufactured in China has been approved for phase-III clinical trials in the Philippines. The V-01 vaccine was developed by the Institute of Biophysics under the Chinese Academy of Sciences and Livzon Pharmaceutical Group Inc. (LivzonBio) in south China's Guangdong Province. V-01 is a fusion recombinant protein vaccine with the receptor-binding domain (RBD) as the antigen. RBD is the most important part of the virus spike protein binding with human cellular ACE2 receptors. The binding process grants the virus access to the host's cells and leads to infection. The Food and Drug...
